Celebrities may have glam squads and access to the best doctors and treatments in the world — and yet even they have skin ...
Johnson & Johnson is counting on its newly launched psoriasis pill to become its next cash cow. Investors want to know if it ...
PIP is now worth up to £778 every four-week period for those on the higher rates of the daily living and mobility components.
Everyday Health on MSN
5 psoriatic arthritis myths and facts
Misconceptions about psoriatic arthritis can make it difficult to diagnose and explain to others.
Psoriasis, which affects over a million people in the UK, could put patients and their family members at risk for a unique form of arthritis. It can affect a range of joints across the body and even ...
Ixekizumab plus tirzepatide (IXE+TZP) shows significant benefits over ixekizumab (IXE) alone in adults with active psoriatic arthritis (PsA) who are overweight or have obesity, according to a study ...
Javascript must be enabled to use this site. Please enable Javascript in your browser and try again. Ends 5/15/26! Stay confident in today’s economy with useful ...
In a dizzying span of seven months in 2022, Bristol Myers Squibb gained FDA approval for three new products, touting each with the potential to achieve $4 billion in peak sales. While multiple myeloma ...
(RTTNews) - Bristol Myers Squibb (BMY) announced that the U.S. Food and Drug Administration has approved Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis (PsA).
If you have psoriatic arthritis (PsA), you may be familiar with sore fingers, stiff wrists, and the frustration of struggling with formerly simple tasks like buttoning a shirt or chopping vegetables.
Philip Mease, MD, discusses the different treatment options now available for patients with psoriasis and psoriatic arthritis. Psoriatic arthritis (PsA) affects roughly 30% of patients with psoriasis, ...
Please provide your email address to receive an email when new articles are posted on . Patients treated with concomitant ixekizumab and tirzepatide met PsA and weight reduction endpoints. Safety data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results